Diabetes :: Byetta study showed comparable blood glucose control to insulin
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced study results comparing treatment with BYETTA(R) (exenatide) injection with insulin glargine in people with type 2 diabetes.